- Teva Pharmaceuticals has updated its full-year revenue forecast, now expecting to make between $16.8 billion and $17.4 billion. Previously, it was projected to be between $16.8 billion and $17.2 billion, with an estimate of $16.9 billion.
- The company has adjusted its expected EBITDA for the year to be between $4.5 billion and $5.0 billion, whereas it had earlier predicted between $4.7 billion and $5.0 billion, with an estimate of $4.86 billion.
- In the second quarter:
- Adjusted earnings per share (EPS) was 66 cents.
- Revenue was reported at $4.18 billion, below the estimated $4.27 billion.
- Austedo generated $495 million in North American revenue.
- Treanda and Bendeka brought in $40 million in North American revenue.
- Copaxone’s revenue was $62 million in North America, $50 million in Europe, and $7 million in international markets.
- Adjusted EBITDA came in at $1.23 billion, surpassing the $1.18 billion estimate.
- Reported debt stood at $17.23 billion.
- EPS was recorded at 24 cents.
- Market sentiment shows 10 buy ratings, no holds, and 1 sell rating for Teva.
A look at Teva Pharmaceutical Industries Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Investors looking at the long-term prospects of Teva Pharmaceutical Industries may find a mixed bag of indicators according to Smartkarma Smart Scores. While the company scores relatively well in areas such as value and momentum with scores of 3, indicating a positive outlook, the scores for dividend, growth, and resilience stand at 1, 2, and 2 respectively. This suggests that despite some strengths in value and momentum, there are areas of concern for Teva Pharmaceutical Industries in terms of its growth potential, financial resilience, and dividend performance.
Teva Pharmaceutical Industries Limited, a pharmaceutical company that operates on a global scale, faces a challenging road ahead with varying scores in key areas. With a business model focused on developing, manufacturing, and marketing generic and branded pharmaceuticals, the company serves customers worldwide. However, its Smartkarma Smart Scores paint a picture of a company that may need to address certain weaknesses, particularly in growth, resilience, and dividend distribution to secure a more robust long-term outlook.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
